Enter Note
Done
Go to previous page in this tab
Session
Poster Session
Diabetic macular edema
calendar_today
Schedule
edit_square
Notes
editor_choice
Credits
Thu, May 09
11:45am - 1:30pm (Pacific)
530
Set Timezone
Timezone
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
PT - Pacific Time
(GMT-07:00) Arizona
MT - Mountain Time
CT - Central Time
ET - Eastern Time
(GMT-05:00) Indiana (East)
—————————–
(GMT-12:00) International Date Line West
(GMT-11:00) Midway Island
(GMT-11:00) Samoa
(GMT-08:00) Tijuana, Baja California
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-06:00) Saskatchewan
(GMT-06:00) Central America
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-05:00) Bogota
(GMT-05:00) Lima
(GMT-05:00) Rio Branco
(GMT-04:30) Caracas
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Manaus
(GMT-04:00) Santiago
(GMT-04:00) La Paz
(GMT-03:30) Newfoundland
(GMT-03:00) Georgetown
(GMT-03:00) Brasilia
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT) Dublin
(GMT) Lisbon
(GMT) London
(GMT) Monrovia
(GMT) Reykjavik
(GMT) Casablanca
(GMT+01:00) Belgrade
(GMT+01:00) Bratislava
(GMT+01:00) Budapest
(GMT+01:00) Ljubljana
(GMT+01:00) Prague
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Warsaw
(GMT+01:00) Zagreb
(GMT+01:00) Brussels
(GMT+01:00) Copenhagen
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) West Central Africa
(GMT+01:00) Amsterdam
(GMT+01:00) Berlin
(GMT+01:00) Rome
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+02:00) Minsk
(GMT+02:00) Cairo
(GMT+02:00) Helsinki
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Istanbul
(GMT+02:00) Jerusalem
(GMT+02:00) Amman
(GMT+02:00) Beirut
(GMT+02:00) Windhoek
(GMT+02:00) Harare
(GMT+02:00) Johannesburg
(GMT+03:00) Kuwait
(GMT+03:00) Riyadh
(GMT+03:00) Baghdad
(GMT+03:00) Nairobi
(GMT+03:00) Tbilisi
(GMT+03:00) Moscow
(GMT+03:00) Volgograd
(GMT+03:30) Tehran
(GMT+04:00) Muscat
(GMT+04:00) Baku
(GMT+04:00) Yerevan
(GMT+05:00) Ekaterinburg
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Calcutta
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Dhaka
(GMT+06:00) Almaty
(GMT+06:00) Novosibirsk
(GMT+06:30) Yangon (Rangoon)
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Bangkok
(GMT+07:00) Jakarta
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Urumqi
(GMT+08:00) Irkutsk
(GMT+08:00) Ulaan Bataar
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Perth
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Darwin
(GMT+09:30) Adelaide
(GMT+10:00) Canberra
(GMT+10:00) Melbourne
(GMT+10:00) Sydney
(GMT+10:00) Brisbane
(GMT+10:00) Hobart
(GMT+10:00) Vladivostok
(GMT+10:00) Guam
(GMT+10:00) Port Moresby
(GMT+11:00) Magadan
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Auckland
(GMT+13:00) Nukualofa
Poster Range:
B0122 - B0176
RE
Moderators:
Charles DeBoer, (Stanford Medicine)
Woong-Sun Yoo
Session Types
Poster Session
Section
Retina
Download Abstracts as PDF
Presentations
Presentation
Poster Session
B0122: Changes in Aqueous Angiopoietin Concentrations during the Induction Phase of Intravitreal Faricimab Injections for Diabetic Macular Edema
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0123: EB-105: A novel tri-specific fusion antibody for diabetic macular edema
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0124: Flare levels after intravitreal injection of brolucizumab for diabetic macular edema
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0125: The Difference of Changes in Ocular Blood Flow after Intravitreal Injection for Diabetic Macular Edema between Aflibercept and Faricimab
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0126: Choriocapillaris OCTA Perfusion Biomarkers for Predicting Visual Outcomes after Anti-VEGF Injection in Diabetic Macular Edema
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0127: Association of anti-VEGF treatment-free interval on long-term visual acuity in patients with branch retinal vein occlusion
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0128: Relationship between Diffuse Retinal Thickening and Visual Outcomes in the Phase 2b Altimeter Trial using Faricimab for Diabetic Macular Edema
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0129: Impact of baseline central retinal thickness (CRT) on vision among patients with diabetic macular edema (DME): post hoc analysis of the phase 2/3 PHOTON trial
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0130: Intraocular pressure outcomes with intravitreal injection of aflibercept 8 mg and 2 mg in patients with diabetic macular edema through Week 48 of the phase 2/3 PHOTON trial
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0131: Real-world safety and efficacy of faricimab for diabetic macular edema in a veteran population
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0132: Correlation of OCT data and biomarkers to treatment response in diabetic macular edema
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0133: Response to anti-VEGF therapy with newer oral hypoglycemic agents in patients with diabetic macular edema
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0134: Retinal blood flow and oxygen saturation before and after intravitreal aflibercept for diabetic macular edema
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0135: Response to anti-VEGF therapy in patients with diabetic macular edema is not affected by insulin use
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0136: Choroidal vascular index has no predictive value on the frequency of intravitreal anti-vascular endothelial growth factor applications in diabetic retinopathy
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0137: National Anti-VEGF Utilization for Conditions without U.S. Food and Drug Administration Approval: An IRIS Registry Study
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0138: Greater reduction in hard exudates with faricimab vs aflibercept in patients with DME: biomarker results from the phase 3 YOSEMITE/RHINE trials
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0139: Developing Laterality-Specific Computable Phenotypes from EMR Data, employing Treatment-Warranted Diabetic Macular Edema (TW-DME) as a use case
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0140: Socioeconomic Factors Impacting Initiation of anti-VEGF in DME: A National Study
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0141: Predictive Value of Macular Thickness Fluctuations on Response to Anti-VEGF Treatment in Diabetic Macular Edema
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0142: Port Delivery System with ranibizumab (PDS) stabilizes retinal nonperfusion and macular leakage: results from Pagoda and Pavilion phase 3 trials in diabetic macular edema (DME) and diabetic retinopathy (DR)
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0143: Port Delivery System With Ranibizumab (PDS) in diabetic macular edema (DME): additional primary analysis results of the phase 3 Pagoda trial
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0144: Pharmacokinetic (PK) profile of the Port Delivery System with ranibizumab (PDS) in the phase 3 Pagoda and Pavilion trials
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0145: Efficacy and Safety of Faricimab in ALTIMETER: A Trial Exploring Biomarkers of Ang-2 Inhibition in Patients With DME
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0146: VIAN-c4551 in eye drops inhibits the excessive retinal vasopermeability induced by VEGF and diabetes in rodents
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0147: Real-world treatment patterns and outcomes in the first 6 and 12 months of faricimab use among eyes with diabetic macular edema (DME) in the UK: FARWIDE-DME
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0148: Outcomes of patients with diabetic macular edema (DME) and baseline best-corrected visual acuity (BCVA) of 20/50 or worse or 20/40 or better who were treated with aflibercept 8 mg and 2 mg: a post hoc analysis of the phase 2/3 PHOTON trial
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0149: Key clinical and anatomic outcomes from the YOSEMITE/RHINE trials of faricimab in patients with DME.
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0150: High retinal and low systemic exposure of EXN407 eye drops in humans, a new topical therapeutic for the treatment of diabetic macular edema (DME)
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0151: Real-world clinical and anatomical outcomes in patients with diabetic macular edema treated with faricimab: The FARETINA-DME study
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0152: Elevatum study design and rationale: a phase 4 trial of faricimab (VABYSMO) in underrepresented patients with DME
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0153: Sociodemographic Variables, Racial Disparity, and OCT-Based Biomarkers as Predictive Factors of DME Refractory to Bevacizumab
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0154: Correlation of functional and anatomical improvement following treatment for Diabetic Macular Edema: a post-hoc analysis
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0155: Early Effect of Intravitreal Faricimab on Hard Exudates in Diabetic Macular Oedema
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0156: Real-world outcomes in patients with diabetic macular oedema treated with faricimab
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0157: Inter-Eye Differences of Vessel Density and Fractal Dimension in Diabetic Patients
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0158: A double-masked, Placebo-Controlled, Phase 1b/2a Study of EXN407 Eye Drops in Patients with Mild Center Involving Diabetic Macular Edema (DME)
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0159: Factors associated with inflammation-related biomarkers on optical coherence tomography (OCT) in patients with diabetic macular edema (DME)
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0160: Macular edema response 24 hours after intravitreal dexamethasone implant: short- and long-term results.
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0161: Structural and functional stability of intravitreal dexamethasone therapy of eyes with diabetic macular edema as assessed by Time-in-Range analysis.
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0162: KSI-501: a bispecific fusion protein antibody inhibiting both interleukin-6 and vascular endothelial growth factor. First-in human-trial results of multiple ascending doses in patients with diabetic macular edema
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0163: Efficacy and safety of a low dose dexamethasone implant for diabetic macular edema and retinal vein occlusion: Results of the First-In-Human Phase 2 RIPPLE-1 trial
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0164: The impact of socioeconomic deprivation on anti-VEGF therapy and ocular response in patients with diabetic macular edema
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0165: Integration of Optical Coherence Tomography in Remote Screenings for Macular Edema in Type 1 Diabetes Mellitus
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0167: Comparison of Portable Retinal Thickness Analyzer and Spectral Domain Optical Coherence Tomography Retinal Thickness Measurements in Diabetic Eyes
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0168: Selecting combinations of visual function measures to identify severity of diabetic retinopathy
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0169: The Real-World Efficacy and Safety of Faricimab in Diabetic Macular Edema: The TAHOE Study
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0170: Outcomes of retinal neurodegenerative changes in patients with diabetic macular edema from the VISTA study
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0171: Regulation of Anti-VEGF Drug Effectiveness by Inflammatory Mediators in Patients with Diabetic Macular Edema
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0172: A randomized, active-controlled, patient and investigator-masked, multiple dose Ph2 study of intravitreal LKA651, an anti-erythropoietin (EPO) antibody fragment, in patients with diabetic macular edema
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0173: Intravitreal Dexamethasone Implant in anti-VEGF Pretreated Diabetic Macular Edema – a Swiss Cohort Study
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0174: Increased amplitude of ultra high frequency (UHF) diameter changes in retinal arterioles from patients with vision threatening diabetic retinopathy.
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0175: The association between tobacco smoking and the development of diabetic macular edema
11:45am-1:30pm May 9 (Pacific)
Presentation
Poster Session
B0176: Epidemiological analysis of optical coherence tomography biomarkers in diabetic macular edema in a Mexican reference center
11:45am-1:30pm May 9 (Pacific)
Discussion
